Chief Scientific Officer
Dr Christopher Chan is an immunologist with expertise in therapeutic antibody development, immuno-oncology, inflammation, innate myeloid and lymphocyte biology, and T cell biology.
Chris has worked in both start-up (Pionyr Immunotherapeutics), and small biotechnology (Compugen USA, Inc) companies in San Francisco, and has experience working in science and technology accelerators, incubators, and leading drug development programs that have led to successful venture capital investments and a merger/acquisition agreement. Chris has led first-in-class antibody development programs from target discovery through to IND-enabling activities, which has culminated in IND clearances by the US FDA and the submission and granting of numerous patents.
Chris completed his PhD in Immunology at Monash University and the Peter MacCallum Cancer Centre in Melbourne, and performed further postdoctoral studies at Oregon Health and Science University in Portland.